Loading...
Please wait, while we are loading the content...
Similar Documents
Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation.
| Content Provider | Europe PMC |
|---|---|
| Author | Park, Shin-Hyung Kim, Jae-Chul |
| Copyright Year | 2020 |
| Abstract | PurposeTo evaluate the necessity of regional nodal irradiation (RNI) for pT1-2N1 breast cancer patients treated with breast-conserving surgery and radiotherapy, we compared clinical outcomes of patients treated with and without RNI.Materials and MethodsWe retrospectively analyzed the data of 214 pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation from 2007–2016. There were 142 (66.4%), 51 (23.85%), and 21 (9.8%) patients with one, two, and three positive lymph nodes, respectively. Thirty-six patients (16.8%) underwent RNI. Adjuvant chemotherapy, endocrine therapy, and anti-HER2 therapy were given to 91.6%, 79.0%, and 15.0% patients, respectively. The most common chemotherapy regimen was anthracycline + cyclophosphamide, followed by taxane (76.5%). The median follow-up was 64 months (range, 6 to 147 months). Patients were propensity matched 1:2 into RNI and no-RNI groups.ResultsTwo patients experienced locoregional recurrences simultaneously with distant metastases, ten patients developed distant metastases, and one patient died. Before matching, the 5-year actuarial locoregional control (LRC), distant metastasis-free survival (DMFS), and overall survival (OS) rates in the RNI and no-RNI groups were 100.0% and 99.4% (p = 0.629), 94.1% and 96.0% (p = 0.676), and 100.0% and 99.4% (p = 0.658), respectively. After matching, the 5-year LRC, DMFS, and OS were 98.3% and 100.0% (p = 0.455), 96.6% and 93.9% (p = 0.557), and 100.0% and 100.0% (p > 0.999) in the RNI and no-RNI groups, respectively. No clinicopathologic or treatment-related factors were significantly associated with LRC, DMFS, or OS.ConclusionAdding RNI did not show superior LRC, DMFS, or OS in pT1-2N1 breast cancer patients. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7113153&blobtype=pdf |
| ISSN | 22341900 |
| Journal | Radiation Oncology Journal [Radiat Oncol J] |
| Volume Number | 38 |
| DOI | 10.3857/roj.2019.00647 |
| PubMed Central reference number | PMC7113153 |
| Issue Number | 1 |
| PubMed reference number | 32229808 |
| e-ISSN | 22343164 |
| Language | English |
| Publisher | The Korean Society for Radiation Oncology |
| Publisher Date | 2020-03-25 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2020 The Korean Society for Radiation Oncology |
| Subject Keyword | Radiotherapy Breast cancer Breast-conserving surgery Lymphatic Radiotherapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging Oncology |
